This research study is being done to learn more about multiple myeloma and if the study drug, GSK2857916, can improve multiple myeloma in patients who have already failed other treatments. We also would like to answer the following questions:
Some parts of this study are research which means they have not been tested yet.
Please note that GSK2857916 is not yet approved for use in people with multiple myeloma.
Yes. You will receive GSK2857916 in a vein over 30 minutes once every 3 weeks on Day 1 of each 21-day cycle.
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.